Brett P. Eaton

TL;DR: These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates, and the broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenavirus, and coronavirus suggests the potential for wider medical use.

TL;DR: It is shown that BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells, and exhibits broad-spectrum antiviral activity against numerous viruses.

TL;DR: This work uses an epitope-agnostic approach to identify six monoclonal antibodies that bind to spike proteins from all seven human-infecting coronaviruses, and highlights the fusion peptide as a candidate epitope for next-generation coronavirus vaccine development.

TL;DR: Promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, and the absence of interaction with glycoprotein-based vaccines.

TL;DR: These results characterize the phenotypic and immunological differences in the host innate response to pathogenic and avirulent Burkholderia strains and provide insight into the phenotypesic alterations and molecular targets underlying host-Burkholderia interactions.